When was Vyome Therapeutics founded?

Vyome Therapeutics was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Vyome Therapeutics located?

Vyome Therapeutics is headquartered in Princeton, United States. It is registered at C4-201,Akshar Pavilion Priya Cinema Road, Vadodara, Vadodara, Gujarat, India, 390021.

Who is the current CEO of Vyome Therapeutics?

Venkateswarlu Nelabhotla of Vyome Therapeutics. They have also founded 1 company.

Which legal entities is Vyome Therapeutics associated with?

Vyome Therapeutics is associated with VYOME BIOSCIENCES PRIVATE LIMITED and 2 others.

How many employees does Vyome Therapeutics have?

As of Apr 30, 2026, the latest employee count at Vyome Therapeutics is 19.

Is Vyome Therapeutics a funded company?

Vyome Therapeutics is a funded company, having raised a total of $62.9M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 02, 2010.

When was the latest funding round of Vyome Therapeutics?

Vyome Therapeutics' latest funding was a $***** Series D round on Dec 31, 2018, with participation from 5 investors.

What is the annual revenue of Vyome Therapeutics?

Annual revenue of Vyome Therapeutics is ₹40.2K as on Mar 31, 2025.

Where does Vyome Therapeutics rank among its competitors?

Vyome Therapeutics ranks 169th amongst 3033 active competitors, of which 1041 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Vyome Therapeutics?

Vyome Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Vyome Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Vyome Therapeutics is a public company based in Princeton (United States), founded in 2010 by Shiladitya Sengupta and Venkateswarlu Nelabhotla. It operates as a Developer of therapeutics for the immuno-inflammatory conditions. Vyome Therapeutics has raised $62.9M in funding from investors like IndoUS Venture Partners, Sabre Partners and Romulus Capital. The company has 3033 active competitors, including 1041 funded and 742 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Developer of therapeutics for the treatment of the immuno-inflammatory conditions. It offers locally-acting drug product which include VB-1953 gel for malignant fungating wound and inflammatory acne, VT1908 for steroid-refractory incompatibe uveitis, and for other rare immunological conditions including arthritis, diabetes, psoriasis, Crohn's disease, blindness, lupus, and others.

Website: vyometx.com
Social
Email ID: *****@vyometx.com
Phone Number: +1 **********
Registered Address: C4-201,Akshar Pavilion Priya Cinema Road, Vadodara, Vadodara, Gujarat, India, 390021

Key Metrics

Founded Year

2010

Location

Princeton, United States

Stage

Public

Total Funding

$62.9M in 7 rounds

Latest Funding Round

Series D, Dec 31, 2018, $*****

Investors

IndoUS Venture Partners & 12 more

Ranked

169^th among 3033 active competitors

Annual Revenue

₹40.2K as on Mar 31, 2025

Employee Count

19 as on Apr 30, 2026

Investment & Acquisitions

Oculo Health

Similar Companies

LEO Pharma & 803 more

Exit Details

Public

View Vyome Therapeutics' full profile

Vyome Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VYOME THERAPEUTICS LIMITED CIN: U73100GJ2017PLC098900 , India, Active	Aug 30, 2017	$397K (As on Mar 31, 2025)	6 (As on Jul 31, 2025)
VYOME BIOSCIENCES PRIVATE LIMITED CIN: U33110GJ2010PTC099141 , India, Active	Aug 19, 2010	$475 (As on Mar 31, 2025)	1 (As on Dec 31, 2022)
VYOME THERAPEUTICS INC. CIN: 6519686 , United States, Active		-	-	-

Vyome Therapeutics got listed on Aug 15, 2025.

Click here to take a look at Vyome Therapeutics's IPO in detail

Vyome Therapeutics has raised a total funding of $62.9M over 7 rounds. Its first funding round was on Nov 02, 2010. Its latest funding round was a Series D round on Dec 31, 2018 for $*****. 5 investors participated in its latest round. Vyome Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Vyome Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 31, 2018	5787466	Series D	3042217	4793390	5020569	5301804
Dec 21, 2018	9116527	Series C	2833918	1797950	2980865	7876638
Dec 14, 2018	1682236	Series C	9728805	6123655	3392890	7627479

Access funding benchmarks and valuations. Sign up today!

View details of Vyome Therapeutics's funding rounds and investors

The founders of Vyome Therapeutics are Shiladitya Sengupta and Venkateswarlu Nelabhotla. Venkateswarlu Nelabhotla is the CEO of Vyome Therapeutics.

Here are the details of Vyome Therapeutics' key team members:

Shiladitya Sengupta: Co-Founder of Vyome Therapeutics. They serve on the board of 1 company.
Venkateswarlu Nelabhotla: Co-Founder & CEO of Vyome Therapeutics.
Contact Info: 1 email address

Vyome Therapeutics' Board of Directors

Vyome Therapeutics's board has 4 active members. Shiladitya Sengupta and Venkateswarlu Nelabhotla are part of team and Ranjana Kumar and Krishna Kumar Gupta are independent board members.

Here is the list of Vyome Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Shiladitya Sengupta	Team	-	Current	15y 9m
Venkateswarlu Nelabhotla	Team	-	Current	7y 2m
Ranjana Kumar	Independent board member	-	Current	15y 6m
huniqxe	Independent board member	-	Current	2y 5m

View details of Vyome Therapeutics's Founder profiles and Board Members

Vyome Therapeutics' employee count trend

Vyome Therapeutics has 19 employees as of Apr 26. Here is Vyome Therapeutics's employee count trend over the years:

Employee count trend for Vyome Therapeutics

Uncover Vyome Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vyome Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Vyome Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
169th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Sabre Partners & 11 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Vyome Therapeutics's competitors? Click here to see the top ones

Founders own 5.22%, Funds (largest shareholder) own 80.66%, ESOP Pool own 6.02% and Other Investors own 8.11%. The net worth of Vyome Therapeutics's founders is INR 13.4Cr as of Sep 28, 2016.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	5.22%	13.4Cr	85377	28101	45466	79474
Shiladitya Sengupta	76418	71219	64972	37695	34548	72573
Fund	80.66%	208Cr	6300404	2262798	4701245	2702269
Kalaari Capital	4538136	3650967	9666502	9352224	4218159	3747709
Perceptive Advisors	6625973	8420965	4978070	2147288	5067482	4349995
Sabre Partners	5541856	4855204	4870866	3661812	2736031	1706893
Romulus Capital	7316	5955	6150	5914	1656	3967
ESOP Pool	6.02%	15.5Cr	629876	979767	488449	980636
Other Investors	8.11%	20.9Cr	1622028	3278543	7496888	7167658
Total	100.00%	257Cr	4039719	2141159	3734016	6494304

To unlock detailed Cap Table of Vyome Therapeutics Sign up today!

Notes: The column Net Worth represents the net worth of investments made by that entity, as per the latest cap table.

Disclaimer

View more details of Vyome Therapeutics's Shareholding

Vyome Therapeutics has acquired Oculo Health. Vyome Therapeutics has not made any investments as of now.

Media has covered Vyome Therapeutics for a total of 22 events in the last 1 year, 9 of them have been about company updates and 3 about people movement.